capecitabine + eribulin + gemcitabine + paclitaxel

This is a combination chemotherapy regimen consisting of four cytotoxic agents—capecitabine, eribulin, gemcitabine, and paclitaxel. Each drug has a distinct mechanism of action targeting cancer cell proliferation and survival: - Capecitabine is an oral prodrug that is converted to 5-fluorouracil (5-FU) in the body, inhibiting thymidylate synthase and interfering with DNA synthesis. - Eribulin is a synthetic analog of halichondrin B that inhibits microtubule dynamics by binding to the growing ends of microtubules, leading to mitotic arrest and apoptosis. - Gemcitabine is a nucleoside analog that incorporates into DNA during replication, causing chain termination and inhibition of DNA synthesis. - Paclitaxel stabilizes microtubules by promoting their assembly and preventing disassembly, thereby disrupting mitosis. This multi-agent regimen would be expected to have broad antitumor activity due to the complementary mechanisms but also carries an increased risk for cumulative toxicity. While combinations such as eribulin plus capecitabine are studied in breast cancer[2][3][4][5], there are no standard regimens or clinical trial data specifically supporting the simultaneous use of all four agents together.